J.-M. L’Orphelin
YOU?
Author Swipe
View article: Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data Open
View article: Skin Rash on Immunotherapy: When Trombicula Mimics a Cutaneous Immune-related Adverse Event
Skin Rash on Immunotherapy: When Trombicula Mimics a Cutaneous Immune-related Adverse Event Open
View article: Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols
Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols Open
Only three combinations of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) targeted therapies are marketed for the treatment of BRAF-mutated metastatic melanoma. The use of these combinations can be limited by the occurrence of severe adve…
View article: The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage
The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage Open
The skin microbiome plays a crucial role in maintaining skin health, defending the body against harmful pathogens, and interacting with melanoma. The composition of the skin microbiome can be affected by factors like age, gender, ethnicity…
View article: Paget’s Disease of the Male Breast: A Diagnostic Challenge
Paget’s Disease of the Male Breast: A Diagnostic Challenge Open
View article: Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study Open
Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven surv…
View article: Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals
Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals Open
Objectives Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after occurrence of an immune-related adverse event (irAE). We aim to identify potential emergent safety signals. Design T…
View article: NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial Open
I the proliferation of intra-tumour CD8+ T cells is directly correlated with the clinical response, making tumour-infiltrating lymphocytes (TILs) a treatment of interest in combination with a PD-1 inhibitor, which is the undisputed gold st…
View article: Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV
Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV Open
Background. Immune checkpoint inhibitors are the undisputed first-line treatment for stage IV melanoma, and are associated with adverse events, often immuno-related. Immune-related events are increasingly taken into account in therapeutic …
View article: Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy
Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy Open
View article: The Place of Avelumab Rechallenging in Metastatic Merkel Cell Carcinoma (MCC) Therapeutic Strategies: About a Case-Report
The Place of Avelumab Rechallenging in Metastatic Merkel Cell Carcinoma (MCC) Therapeutic Strategies: About a Case-Report Open
View article: An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report Open
Mogamulizumab is a monoclonal antibody that binds to C–C chemokine receptor 4 (CCR4), initiating antibody-dependent cellular cytotoxicity. CCR4 is highly expressed in the cutaneous T-cell lymphoma subtypes mycosis fungoides and Sézary synd…
View article: NIVO-TIL: Combination anti-PD-1 and adoptive T-cell transfer in metastatic melanoma: a proof of concept
NIVO-TIL: Combination anti-PD-1 and adoptive T-cell transfer in metastatic melanoma: a proof of concept Open
Introduction : Metastatic melanoma patients responding to anti-PD-1 therapy showed proliferation of intra tumoral CD8+ T-cells directly correlated with clinical response, making Tumor-infiltrating lymphocytes (TILs) a potential curative tr…
View article: Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study Open
Background Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune‐related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40%…
View article: Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma Open
Background: Checkpoint inhibitors, such as PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab), are widely used in metastatic melanoma, and most immune-related adverse events are known. Several cardiovascular AE…
View article: Complete remission after imiquimod Monotherapy Treatment of LM: A Case Report
Complete remission after imiquimod Monotherapy Treatment of LM: A Case Report Open
View article: Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study Open
Background: Cemiplimab is a monoclonal antibody targeting the PD-1, and phase II trials have shown its efficacy in the treatment of advanced cutaneous squamous cell carcinoma in patients who are not candidates for curative surgery or radia…
View article: Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study Open
Background: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are rare, aggressive cutaneous T-cell lymphomas that may be difficult to treat. Mogamulizumab is a recent monoclonal antibody targeting the CCR4 receptor expressed on the…
View article: Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases Open
Background: For several decades, PD-1 has been a target in malignant melanoma (MM). PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) have revolutionized cancer therapy. PD-1 and CTLA-4 inhibition leads to pro…